Title page:

1

6

- 2 Full title: Impact of statin withdrawal on perceived and objective muscle function
- 3 Short title: Statin withdrawal and perceived and objective muscle function
- 4 Paul Peyrel^{1,2}, Pascale Mauriège^{1,2}, Jérôme Frenette^{3,4}, Nathalie Laflamme³, Karine
- 5 Greffard³, Sébastien S. Dufresne⁶, Claire Huth^{1,2}, Jean Bergeron^{3,5}, Denis R. Joanisse^{1,2,*}
- ¹Department of Kinesiology, Université Laval, Québec, Québec, Canada
- 8 ²Research Center of the University Institute of Cardiology and Pulmonology of Quebec,
- 9 Québec, Québec, Canada
- 10 ³CHU de Québec Université Laval Research Center, Québec, Québec, Canada
- ⁴Department of Rehabilitation, Université Laval, Québec, Québec, Canada
- ⁵Department of Laboratory Medicine and of Medicine, Université Laval, Québec, Québec,
- 13 Canada
- 14 ⁶Department of Health Sciences, Université du Québec à Chicoutimi, Saguenay, Québec,
- 15 Canada

- * Corresponding author:
- 18 Email: denis.joanisse@kin.ulaval.ca (DRJ)

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

Abstract Background and Aims: Statin-associated muscle symptoms (SAMS) are frequently reported. Nevertheless, few data on objective measures of muscle function are available. Recent data suggesting an important nocebo effect with statin use could confound such effects. The objective was to assess if subjective and objective measures of muscle function improve after drug withdrawal in SAMS reporters. Methods: Patients (59 men, 33 women, 50.3±9.6 yrs.) in primary cardiovascular prevention composed three cohorts: statin users with (SAMS, n=61) or without symptoms (No SAMS, n=15), and controls (n=16). Force (FO), endurance (EN) and power (PO) of the leg extensors (EXT) and flexors (FLE) and handgrip strength (FOHG) were measured using isokinetic and handheld dynamometers, respectively. A 10-point visual analogue scale (VAS) was used to self-assess SAMS intensity. Measures were taken before and after two months of withdrawal. Results: Following withdrawal, repeated-measures analyses show improvements for the entire cohort in ENEXT, ENFLE, FOFLE, POEXT and POFLE (range +7.2 to +13.3%, all $p \le 0.02$). Post-hoc analyses show these changes to occur notably in SAMS (+8.8 to +16.6%), concurrent with a decrease in subjective perception of effects in SAMS (VAS, from 5.09 to 1.85). FOHG was also improved in SAMS (+4.0 to +6.2%) when compared to No SAMS (-1.7 to -4.2%) (all p=0.02). Conclusions: Whether suffering from "true" SAMS or nocebo, those who reported SAMS had modest but relevant improvements in muscle function concurrent with a decrease in subjective symptoms intensity after drug withdrawal. Greater attention by clinicians to

muscle function in frail statin users appears warranted.

1. Introduction

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

Among the pharmacological approaches used to treat hypercholesterolemia, statins are considered the reference lipid-lowering drugs (1). By significantly reducing cholesterol synthesis through HMG-CoA reductase inhibition, they are commonly used as part of primary or secondary prevention to limit the risk of cardiovascular disease (CVD). Statins are now used by over 200 million people around the world (2), but controversies remain on the nature and prevalence of their side effects. These effects can include the development of diabetes, elevated circulating liver enzymes and joint pain (3, 4), but statinassociated muscle symptoms (SAMS) are the most frequently reported side effects of statin use. Mild myalgia has often been reported by 5-10% of statin users (4, 5), this rate reaching around 20% in a few reports (6, 7). That statin use could lead to a variety of mild or moderate muscle symptoms is not surprising. Indeed, myopathies and rhabdomyolysis have been documented from statin use (8-10), giving credence to the idea that less severe symptoms are possible or even likely. Nevertheless, recent work has called into question the true prevalence of SAMS, as distinguishing between the harmful effects truly associated with statins and the so-called nocebo effect is not trivial (11-14). It is thus essential to develop strategies in order to identify the "true" statin-intolerant patients (15). Among those proposed is the recent "SAMS - Clinical Index" (SAMS-CI) (16) which purports to classify the origin of muscle pain according to whether it is "unlikely", "possibly" or "probably" related to statin use. This tool remains to be validated for use in a broad patient population. While statins promote an increase in reported muscle complaints, in different muscle groups (especially pectorals, quadriceps, biceps, and deltoids) (17), they do not appear to

66

67

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

lead to a systematic decrease in strength or endurance, physical activity level or performance (18-23). A recent study by Kawai et al. (2018) (24) assessed the physical performances of 1,022 adults aged between 65 and 88 vrs., depending on whether the participants were using statins or not. In this study, significantly lower handgrip strength (respectively 26.1 \pm 7.4kg and 28.1 \pm 8.5kg, mean \pm standard deviation [SD]) and normal walking speed (respectively 1.30±0.24m/s and 1.36±0.26m/s) were observed between statin users compared with non-users. However, when these data were adjusted for SAMS risk factors (age, sex, body mass index [BMI], and number of medications), differences were lost, suggesting that SAMS were contributory to these effects. The current state of the scientific literature is both limited and contradictory. Some studies suggest that SAMS have no impact on muscle performance (25, 26). However, as illustrated by Parker et al. (2013), a reduction in performance has been previously demonstrated in patients reporting SAMS in some observational studies (22). Nevertheless, in the work of Parker et al. (2013), while a decrease in 5 of the 14 performance variables studied did occur in statin patients reporting SAMS (n=18), 4 performance variables also deteriorated in patients reporting muscle symptoms in the placebo group (n=10). In general, the probability that studies examining the muscle function effects of statins include both true SAMS-sufferers and nocebo reporters certainly is a limiting factor in the current understanding of this phenomenon. The present study therefore aimed first to focus on the effects of statin withdrawal on perceived SAMS and objective muscle performance, and second to explore the impact of this manipulation according to the SAMS-CI category.

2. Methods

87

88

89

90

91

92

93

94

95

96

97

98

99

100

101

102

103

104

105

106

107

108

109

2.1 Participants

Caucasian men (n=59) and women (n=33) aged 30 to 60 years (50.3 \pm 9.6 yrs. [mean \pm SD]) and affiliated to the cardiovascular (CV) lipid prevention clinic at the CHU de Québec-Université Laval (CHUL) were enrolled. These were patients treated with statins in primary CV prevention and with normal blood creatine kinase (CK) levels. Two statin groups were formed: a first self-reporting SAMS (SAMS, n=61) and a second without SAMS (No SAMS, n=15). A third group of participants not taking statins served as controls (Controls, n=16). In this work, data are pooled from a pilot study and a main study (Fig 1). In both studies, the inclusion and exclusion criteria and procedures, with a few exceptions mentioned below, were the same. Participants had to be in good general health, sedentary or moderately active (i.e., less than one hour of leisure-time physical activity performed per week) and to present no contraindications for physical function testing. Patients were required to have a low or moderate Framingham risk score, which allowed the research team to modify their lipid-lowering regimen for the study period. Finally, patients who were previously prescribed other statins or doses prior to their current regimen were not excluded. However, self-reported SAMS needed to be temporally associated with statin use and be present with the current prescription. Participants were excluded from the study if they had taken other lipid-lowering drugs or any natural treatment that affects lipid metabolism in the last year. Other exclusion criteria included vitamin D deficiency (calcifediol (25(OH)D₃) levels below 12.5nmol/L) or vitamin D supplementation; elevated circulating CK levels (>170u/L for women; >195u/L for men) or a history of elevated CK of known or unknown etiology; hepatic or

111

112

113

114

115

116

117

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132

renal failure; untreated hypo- or hyperthyroid; any treatment promoting an increased risk of myopathy; any infection requiring the use of an antibiotic; a daily consumption of more than 60mL of grapefruit juice; hereditary muscle disorders or myopathy, polymyositis or inflammatory myopathy; use of corticosteroids; comorbidities leading to muscle or bone pain (fibromyalgia, arthritis, sensory or intrinsic neuropathy, spinal disease, loss of reflexes, atrophy muscle group); unexplained cramps; cancer in the five years prior to entry into the study; diabetes, stroke, or any known sickle cell trait. In addition, pregnancy, breastfeeding, a physical disability or previous injury interfering with stress testing, depression (within the past three years) or treatment with antidepressants, the use of antipsychotic drugs and alcohol abuse were also exclusion factors. In a subset of participants (n=22) for which data were available, comparisons based on SAMS-CI category were performed for SAMS-reporting participants (16). The protocol was approved by the CHU de Québec – Université Laval ethics committee, and all participants provided informed written consent. The study design complied with the principles of the Declaration of Helsinki and was registered in clinicaltrials.gov (NCT01493648). Recruitment and data acquisition were conducted from October 2011 to October 2015. <insert Fig 1 here> Fig 1. Diagram of patients' recruitment M: men; SAMS: statin-associated muscle symptoms; W: women. 2.2 Procedures

134

135

136

137

138

139

140

141

142

143

144

145

146

147

148

149

150

151

152

153

154

155

Participants first participated in an inclusion visit. Height (stadiometer), body mass (calibrated scale), BMI (kg/m²), and waist circumference (WC) were assessed (weight, BMI, and WC were not measured after statin withdrawal in the pilot study). Participants completed a standardized recruitment questionnaire, based on current statin type and dosage, stating use history, predisposing conditions or factors that could contribute to muscle problems, as well as an assessment of eating habits. The experimental protocol consisted of two months of statin withdrawal with pre- and post-withdrawal assessments of subjective and objective measures of muscle function and blood levels of several markers of interest. Data were collected by a blinded experimenter. On the day of pre-test, participants were instructed to take their usual dose of statin at their habitual time. The two-month interval was based on previous studies that showed most SAMS appeared or were resolved within this period of the introduction or withdrawal of the medication (5, 27). 2.3 Measurements 2.3.1 Self-reported muscle symptoms Participants self-reported the presence of SAMS by describing what symptom(s) they believed to be the result of medication use. These symptoms typically included myalgia, stiffness, weakness, fatigue and/or cramps. They were then asked to rate the intensity of the symptom(s) they reported by answering the following question (translated from French) on a visual analog scale (VAS): On a scale of 0 to 10 (10 being the most intense or unbearable), rate the current intensity of the symptom(s) which you believe to be related to statin use

157

158

159

160

161

162

163

164

165

166

167

168

169

170

171

172

173

174

175

176

177

178

2.3.2 Blood tests A venipuncture was performed following a 12-h overnight fast and prior to muscle function tests. The levels of a number of circulating factors were assessed from these samples (Table 1 and S1 Table), including markers of muscle (CK and myoglobin [MB]) and liver (alanine aminotransferase [ALT] and aspartate aminotransferase [AST]) damage, the plasma lipid-lipoprotein profile (total cholesterol [TC]; triglycerides [TG]; high density lipoprotein [HDL]; low-density lipoprotein [LDL]; TC/HDL; apolipoprotein B-100 [APOB-100] and apolipoprotein A1 [APOA1]), and 25(OH)D₃. Only ALT, AST and CK were assessed in the pilot study. All were measured using standardized clinical assays at the CHU de Québec – Université Laval clinical laboratory. 2.3.3 Muscle performance Muscle performance was assessed using a Biodex isokinetic dynamometer (Biodex Medical Systems, Shirley, NY). The system has shown good reproducibility in the healthy population (28). Patients were seated in an upright position and the resistance pads were aligned according to the manufacturer's instructions. The maximum force (FO), power (PO) and endurance (END) of the extensor (EXT) and flexor (FLE) muscles of the dominant leg were measured. Testing began with a warm-up consisting of five repetitions at 60°/s including one movement at maximum voluntary contraction (MVC). Subsequently, the maximum force (Nm) was measured during three MVCs each at 60°/s and 180°/s. The highest measured value was retained. Endurance and power were measured over 15 MVC repetitions at 180°/s. Endurance was calculated as the total (sum) of strength developed during all 15 repetitions (Nm). Power was calculated (W) by multiplying the endurance value with the total time required for the patient to complete the repetitions; then divided by the number of repetitions (n=15). For all tests, each maximum contraction was performed within the first 90 degrees of the knee's range of motion.

2.3.4 Handgrip strength

Handgrip strength was measured with a Jamar hydraulic hand dynamometer (Asimov Engineering, Los Angeles, CA). This tool is reliable and validated (29). Patients performed the test seated with their feet slightly apart, the unassessed arm at their side, the arm assessed at 90° and not resting on an armrest. The handle of the dynamometer was adjusted so that the handle rested on the middle of the four fingers while positioning the base of the dynamometer on the first metacarpal. Once in position, the patient was asked to squeeze the handle of the dynamometer as hard as possible for 3s while exhaling. One min of rest between each contraction was respected. The best of the three repetitions was retained to assess handgrip force (kg) in the right (FOHGR) and left (FOHGL) hands In the pilot study, handgrip strength was only measured in the dominant hand.

2.4 Statistical analyses

Data are expressed as mean \pm SD. Sample size calculations were performed using predicted changes to measures of physical performance following statin withdrawal. Using a one-tailed model with p=0.01 and a power of 80% and aiming for a 20% average increase

in several muscle function tests using observed standard deviations (SD) from preliminary data from 9 participants, required total n values were found to range from 15 to 30.

All statistical analyses were performed using JMP software (SAS Institute, Cary, NC). In cases of missing data for any given measure, participants were removed from that analysis. Between group differences for variables not measured repeatedly over time were analyzed by ANOVA followed by Tukey post-hoc tests. A repeated measures factorial design was used to assess differences between groups and over time using the "Full factorial mixed design" add-in for JMP (30), and post-hoc analyses performed using Tukey tests. Chi-square tests were used to assess distribution differences across groups from contingency tables. These latter tests were not performed when expected observations in a cell fell below n=5. All results were considered statistically significant when p reached <0.05. Finally, Cohen's d values for pairwise comparisons were used to assess effect sizes (ES) for within-group changes over time and to qualify changes as trivial (Cohen's d <0.2), small (0.2-0.5), moderate (0.5-0.8), or large (>0.8).

3. Results

3.1. Anthropometric and metabolic variables at baseline

Participants' characteristics are shown in Table 1. Whereas the SAMS group was significantly older on average (+10.6 yrs.) than the Control group, the No SAMS group was intermediate (5.4 yrs. younger than SAMS) but not significantly different from the other two groups. Overall, the SAMS group presented a slightly more deteriorated health profile, as revealed by higher BMI (+4.1kg/m²) compared to the No SAMS group. Increased adiposity in the SAMS group was also indicated by a greater WC, on average +11.2 cm more than that of the No SAMS and Control groups (p=0.01). Despite a significantly higher ALT level in the SAMS group compared to other groups, all markers of muscle and liver injuries (CK, MB, AST, and ALT) were below values of clinical concern. Finally, 25(OH)D₃ values did not differ between groups and were not indicative of vitamin D deficiency.

Table 1. Pre- and post-statin withdrawal anthropometric characteristics and metabolic variables

	SAMS			No SAMS			Controls			ANOVA		
	SA	IVIS		NO S.	AMS		Conti	015		Time	Category	/ T*C
-	Pre	Post	ES	Pre	Post	ES	Pre	Post	ES	- р	p	р
Men/Women, n	38/	/23		10)/5		11/	5		-	0.87\$	
Age (years)	53.0 ± 8.4^{a}	-	-	47.6 ± 9.6^{ab}	-	-	42.4 ± 9.4^{b}	-	-	-	< 0.01	-
Anthropometric characteristics												
n	37 t	o 59		14 to	o 15		14 to	15				
Height (cm)	166 ± 13^{a}	-	-	172 ± 8^{a}	-	-	169 ± 8^{a}	-	-	-	0.20	-
Weight (kg)	80.9 ± 14.7	80.8 ± 14.7	0.00	74.0 ± 12.3	73.9 ± 12.0	-0.01	74.8 ± 13.3	74.8 ± 13.9	-0.01	0.76	0.10	0.97
BMI (kg/m^2)	29.2 ± 4.5	29.0 ± 4.5	-0.06	25.1 ± 3.2	25.1 ± 3.2	0.00	26.9 ± 5.9	26.9 ± 5.9	0.00	0.56	0.01	0.66
WC (cm)	95.4 ± 17.2	93.9 ± 10.1	-0.07	86.2 ± 11.1	86.4 ± 11.5	0.01	84.3 ± 13.0	85.1 ± 13.8	0.05	0.93	< 0.01	0.77
Plasma metabolic var	riables											
n	41 t	o 60		1	4		15					
$MB (\mu g/L)$	29.9 ± 11.0	28.5 ± 9.3	-0.13	29.5 ± 10.7	27.9 ± 11.9	-0.18	33.7 ± 18.1	30.8 ± 10.4	-0.08	0.13	0.46	0.84
CK (U/L)	130 ± 76	126 ± 90	-0.11	132 ± 62	118 ± 46	-0.17	163 ± 112	162 ± 88	0.06	0.19	0.25	0.65
ALT (U/L)	30.0 ± 17.6	$26.9 \pm 15.6^*$	-0.22	23.6 ± 12.0	19.1 ± 8.2	-0.30	18.6 ± 5.5	18.4 ± 6.3	-0.04	< 0.01	0.02	0.20
AST (U/L)	22.5 ± 5.9	21.7 ± 6.4	-0.17	22.0 ± 6.3	20.6 ± 5.3	-0.20	19.7 ± 5.1	18.5 ± 4.2	-0.15	0.04	0.15	0.92
TC (mmol/L)	4.81 ± 0.98	$6.78 \pm 1.34^*$	1.73	4.60 ± 0.84	$6.85 \pm 1.37^*$	1.92	5.06 ± 0.83	5.21 ± 0.93	0.16	< 0.01	0.04	< 0.01
TG (mmol/L)	1.89 ± 1.22	2.19 ± 1.20	0.31	1.08 ± 0.54	1.66 ± 0.90	0.70	1.15 ± 1.05	1.20 ± 1.07	0.03	< 0.01	< 0.01	0.22
HDL (mmol/L)	1.31 ± 0.37	1.31 ± 0.35	-0.01	1.55 ± 0.42	1.49 ± 0.44	-0.16	1.56 ± 0.41	1.63 ± 0.42	0.16	0.93	0.03	0.08
LDL (mmol/L)	2.71 ± 0.97	$4.59 \pm 1.31^*$	1.86	2.56 ± 0.71	$4.61 \pm 1,26^*$	2.02	3.11 ± 0.92	3.18 ± 1.03	0.04	< 0.01	0.26	< 0.01
TC/HDL (mmol/L)	3.95 ± 1.36	$5.54 \pm 1.80^*$	1.10	3.09 ± 0.64	$4.82 \pm 1.07^*$	1.85	3.48 ± 1.26	3.45 ± 1.33	-0.04	< 0.01	< 0.01	< 0.01
APOB-100 (g/L)	0.93 ± 0.26	$1.41 \pm 0.33^*$	1.69	0.87 ± 0.17	$1.36 \pm 0.28^*$	2.13	0.91 ± 0.22	0.93 ± 0.28	0.05	< 0.01	< 0.01	< 0.01
APOA1 (g/L)	1.47 ± 0.22	1.44 ± 0.24	-0.11	1.56 ± 0.24	1.54 ± 0.25	-0.09	1.61 ± 0.23	1.60 ± 0.20	0.00	0.36	0.09	0.81
$25(OH)D_3 \text{ (mmol/L)}$	74.2 ± 32.5	$68.4 \pm 32.0^{\dagger}$	-0.18	71.2 ± 27.0	63.8 ± 25.0	-0.25	66.9 ± 18.7	68.3 ± 19.2	0.06	0.02	0.91	0.12
Self-reported muscle symptoms intensity												
n	6	0		1	4	<u> </u>	15		<u> </u>	<u> </u>		
VAS (0 to 10)	5.09 ± 1.81	$1.85 \pm 2.25^*$	-1.22	0.00 ± 0.00	0.00 ± 0.00	/	0.00 ± 0.00	0.00 ± 0.00	1	<0.01	< 0.01	< 0.01

Data are expressed as mean ± standard deviation; \$ P-value is shown here by a chi-squared test; Post value with * is statistically different

from the pre value with $p \le 0.01$; Post value with \dagger is statistically different from the pre value with p < 0.05. ALT: alanine aminotransferase;

APOA1: apolipoprotein A1; APOB-100: apolipoprotein B-100; AST: aspartate aminotransferase; BMI: body mass index; WC: waist circumference; CK: creatin kinase; ES: effects size; HDL: high-density lipoprotein; LDL: low-density lipoprotein; MB: myoglobin; SAMS: statin-associated muscle symptoms; TC: total cholesterol; TC/HDL: cholesterol total / HDL cholesterol; TG: triglycerides; VAS: visual analogic scale; 25(OH)D₃: Calcifediol.

237

238

239

240

241

242

243

244

245

246

247

248

249

250

251

252

253

254

255

256

257

258

3.2. Clinical aspects of statin users Most statin users in this study were prescribed rosuvastatin (50% of participants) or atorvastatin (35.5%). This distribution was expected given the usual clinical practice at the CHU de Québec – Université Laval lipid clinic. A detailed breakdown of the clinical profile of participants in this study is presented in S2 Table. The Framingham Score revealed that the CV risk over ten years was low (<10%) for all patients (except for 1 patient [13%, moderate risk]). Nevertheless, the CV risk for the SAMS group was on average 1.43% and 1.96% higher than that of the No SAMS and Control groups, respectively. Most participants in the SAMS and No SAMS groups had been using statins for 12 to 48 months (80.4% and 100% respectively). Nineteen participants indicated having previously not tolerated some forms of statins, their distribution being roughly equal in SAMS and No SAMS groups (respectively 31.9% and 26.7% of participants). Among the 38 participants with a family history (first degree) of CVD, 35 were present in groups treated with statins. 91.3% of participants with a family history (first degree) in terms of lipid-lowering treatment were present in these same statintaking groups. Finally, of the 30 participants in the SAMS group who reported a family history (first degree) of lipid-lowering therapy, 6 also reported a self-reported family history of SAMS. Statin withdrawal effects on anthropometry and metabolic variables *3.3.* No changes to anthropometric measures were observed following statin withdrawal in either the SAMS or No SAMS groups (Table 1).

260

261

262

263

264

265

266

267

268

269

270

271

272

273

274

275

276

277

278

279

280

In addition, and as expected, a significant deterioration of the lipid-lipoprotein profile was seen in all statin users following drug withdrawal. Indeed, repeated-measures ANOVA analyses revealed several time, category, and time x category interactions for most lipids (Table 1). In brief, while no change was observed in any lipid levels studied in the control group in the same period, both SAMS and No SAMS statin users experienced a deteriorated lipid-lipoprotein profile, reflected by increased TC, TG, LDL, TC/HDL, and APOB-100 levels following medication withdrawal. HDL and APOA1 levels remained, however, unchanged. With respect to markers of tissue damage or dysfunction, while ALT and AST levels are somewhat reduced following withdrawal of the drug, these values always remained well below clinical thresholds. The muscle damage specific markers MB and CK did not differ across groups or change following statin withdrawal and remained well below clinical values of clinical concern throughout the study (Table 1). Finally, despite a small decrease in 25(OH)D₃ levels in the statin groups, these values remained not different from those of the control group and were not indicative of vitamin D deficiency. The baseline levels and impact of statin withdrawal on several other plasma variables are presented in S1 Table. Perceived muscle effects and objective physical performance *3.4.* As depicted in Table 1, a significant improvement in the perception of muscle symptoms following statin withdrawal was observed in the SAMS group, decreasing by 3.24 units on the 10-point scale.

282

283

284

285

286

287

288

289

290

291

292

293

294

295

296

297

298

299

300

301

302

303

Results related to objective physical performance showed significant time effects for all Biodex isokinetic dynamometer measures: ENEXT (+8.17% overall for the entire group [ES: 0.22, small effect]), ENFLE (+11.6% [ES: 0.30, small effect]), FOFLE (+7.20% [ES: 0.22, small effect]), POEXT (+9.04% [ES: 0.24, small effect]) and POFLE (+13.3% [ES: 0.34, small effect]), except for FOEXT (+3.24%, NS, [ES: 0.11, trivial effect]) (Fig 2). However, few between group differences were seen at baseline, with only ENFLE and POFLE being slightly lower in the SAMS group. Although there was no time x category interaction for any of these measures, post-hoc analyses revealed statistically significant within-group improvements only in the SAMS group following statin withdrawal, and this was true for five of the six isokinetic dynamometer measures (improvement range +8.8 to 16.6%, [ES: 0.25 to 0.39, all small effects]). In terms of handgrip performance, although neither left (FOHGL) nor right (FOHGR) force showed any time or category effects, a significant interaction was observed for FOHGL, and this reached near statistical significance (p=0.06) for FOHGR. In both cases, the greatest increase in force following statin withdrawal was seen in the SAMS group (+4.0% for FOHGR [ES: 0.09, trivial effect]; +6.2% for FOHGL, [ES: 0.18, trivial effect]), while values decreased in the No SAMS group (-4.2% for FOHGR [ES: -0.16, trivial effect]; -1.7% for FOHGL [ES: -0.06, trivial effect]). Indeed, if repeated-measure analyses are done without the Control group, the time x category interactions become statistically significant both for the right and left hands (all p=0.02). <insert Fig 2 here>

Fig 2. Pre- and post-statin withdrawal measures of physical performance

Data are expressed as mean ± standard error; Post value with * is statistically different from pre value with p≤0.01; Post value with † is statistically different from pre value with p<0.05; ENEXT: endurance in extension (panel A); ENFLE: endurance in flexion (panel B); FOEXT: force in extension (panel C); FOFLE: force in flexion (panel D); FOHGL: hand grip force left (panel H); FOHGR: hand grip force right (panel G); POEXT: power in extension (panel E); POFLE: power in flexion (panel F); SAMS: statin-associated muscle symptoms.

In order to establish whether observed changes in muscle functions are of clinical relevance, we codified as clinically significant any improvement greater or equal to 15% from baseline for any measure in a given individual (31). The number of patients from the two statin-using groups showing such improvements is reported in Table 2, and contingency analyses revealed that for five of the eight physical performance measures, the number of patients who experienced a clinical improvement in performance following statin weaning was statistically higher in the SAMS group.

Table 2. Proportion of patients who display clinically relevant performance improvements following statin withdrawal

	SAMS n / total (%)	No SAMS n / total (%)	Category p
ENEXT	23/54 (42.6)	2/13 (15.4)	0.05
ENFLE	28/54 (51.9)	4/13 (30.8)	0.17
FOEXT	9/54 (16.7)	1/13 (7.69)	0.38
FOFLE	13/54 (24.1)	2/13 (15.4)	0.49
POEXT	22/54 (40.7)	1/13 (7.69)	0.01
POFLE	29/54 (53.7)	3/13 (23.1)	0.04
FOHGR	6/32 (18.8)	0/12 (0.00)	0.04
FOHGL	7/25 (28.0)	0/12 (0.00)	0.01

323

324

325

326

327

328

329

330

331

332

333

334

335

336

337

338

339

340

341

342

343

344

Data are expressed as the number of patients with a 15% improvement in performance following statin withdrawal / total number of patients in the considered group; p-values are shown here by a chi-squared test. SAMS: statin-associated muscle symptoms; For the other abbreviations, see legends to Fig 2. *3.5.* Targeting "real" sufferers of SAMS For a subset (n=22) of SAMS-reporting patients, available data allowed us to assess the likelihood of their symptoms being truly caused by statins using the SAMS-CI (16). Given very low numbers in the "unlikely" category, they were pooled with the "possible" category for analyses. Subjective perception of symptoms resolution was greater in the patients classified as "probable" for suffering from true SAMS using this classification scheme (Fig 3). However, despite improvement in five of eight measures of physical performance following statin withdrawal, we did not observe any significant difference between categories or category x time interactions in repeated measures analyses (Fig 4). <insert Fig 3 here> Fig 3. Impact of statin withdrawal on perceived SAMS intensity by SAMS-CI category using a visual analog scale from 0 to 10 Data are expressed as mean \pm standard error; Post value with * is statistically different from pre value; SAMS: statin-associated muscle symptoms; SAMS-CI: SAMS – clinical index. <insert Fig 4 here> **Fig 4.** Impact of statin withdrawal on physical performance by SAMS-CI category

Data are expressed as mean \pm standard error; Post value with * is statistically different from pre value with p \leq 0.01; Post value with † is statistically different from pre value with p \leq 0.05; SAMS-CI: statin-associated muscle symptoms – clinical index; For the other abbreviations, see legends to Fig 2.

4. Discussion

349

350

351

352

353

354

355

356

357

358

359

360

361

362

363

364

365

366

367

368

369

370

371

In the face of frequent reports of SAMS (4-7), few objective data have shown negative impacts of statins on muscle performance. Here we present evidence for modest but relevant improvements on muscle function following statin withdrawal in patients selfreporting SAMS. Indeed, despite the lack of change in biochemical markers or clinical indication of tissue damage, we observe for the entire cohort an overall improvement over time following withdrawal in muscle functions for several objective measures of knee extension and flexion (Fig 2). However, upon closer inspection, the greatest improvements were observed in the SAMS group; in fact, within-group analyses showed no statistically significant changes in the No SAMS and Control groups over time. Although the impact of SAMS on performance remains debatable in the literature, our data aligned with those of Parker et al. (2013) that showed differences in leg strength during isokinetic movements in extension at 60°/s and 180°/s and flexion at 60°/s between atorvastatin-treated participants with or without muscle complaints (22). It is perhaps not surprising that we observed an impairment in knee extension and flexion performances, as it has been shown that SAMS tend to affect large muscle groups such as the quadriceps (17). Nevertheless, and unlike that was reported by Parker et al. (2013) (22), we also observed significant though modest improvements in handgrip strength in the SAMS reporting group. Using a cut-off value (15%) which can be considered clinically relevant and a value greater than what is expected from test habituation, we showed a clearly greater proportion of patients showing improvement in objective measures of muscle performance when reporting SAMS (Table 2). Though the average values of the improvements are modest, they are potentially important because they result in a decrease in the potential to perform

373

374

375

376

377

378

379

380

381

382

383

384

385

386

387

388

389

390

391

392

393

394

daily activities. Also, as muscle performance decreases with aging, the impact of such a decrease in performance with statin use could be clinically more significant in this population, which certainly merits further examination. Our data must, of course, be nuanced in the context of a growing body of evidence for a large nocebo effect in patients self-reporting SAMS (12-14, 32). For example, the work of Howard et al. (2021) showed that most symptoms induced by statins were nocebo (32). In the study, the investigators set up a 12-month multi-crossover trial in which 46 patients in primary CV prevention and 14 patients in secondary CV prevention (65.5±8.6 yrs.) were randomized in three conditions: statin, placebo, and no treatment. Every day, patients were asked to rate the intensity of statin-associated symptoms (SAS). Results notably showed differences in self-reported SAS intensity between the statin vs. no treatment and placebo vs. no treatment conditions (p<0.01), though no difference between the placebo and statin conditions was observed (p=0.39). Though their work studied patients who reported SAS, it did not specifically focus on SAMS. Whether or not our patients suffered of "true" SAMS or a confounding nocebo effect, our data showing an objective impact of statin withdrawal on self-reported symptoms intensity and objective measures is of important potential clinical relevance. Indeed, recognizing that a patient could be suffering, objective impacts on muscle functions could and should be considered in treatment assessment and follow up. It is of great importance to develop or validate tools that purport to identify likely sufferers of "true" SAMS (15). In this regard, a subset of our data allowed us to classify participants according to the SAMS-CI, a tool that has been proposed as potentially useful in a clinical setting but has yet to be validated (16). Using this approach, while we did

396

397

398

399

400

401

402

403

404

405

406

407

408

409

410

411

412

413

414

415

416

417

observe a greater improvement in subjective symptoms resolution in those classified as "probably" suffering from SAMS (Fig 3), we did not see any difference in objective measures between categories (Fig 4). These results should be interpreted with great caution as our analyses are weakened by a relatively low number of participants. Nevertheless, the demonstration of a greater subjective impact in the "probably" group does warrant further study on the potential usefulness of the SAMS-CI. This study has several strengths. First, the lipid data indicate that we can be confident about compliance with statin withdrawal. Second, the inclusion of a No SAMS group and a Control group allows a more rigorous analysis and interpretation of results, even if these groups are somewhat smaller. Third, the use of validated and standardized sensitive objective measures allows us to discern little but real effects in muscle function. This study is also, to our knowledge, the first work to attempt to validate the SAMS-CI. Finally, the population recruited here represents a typical population of primary CV prevention patients treated with statins, which reinforces the clinical relevance of our data. A limitation of this study is that recruitment was based on self-reporting of SAMS. Even if we limited the sources of bias using various recruitment criteria, we cannot be certain of the potential influence of the nocebo effect on our results. On the other hand, considering the growing interest in patient-reported outcomes in clinical studies and especially their unique ability to be a true reflection of a "patient-centered approach" (33), further insights into how individuals experience their SAMS and respond to quantitative changes in objective clinical measures can enrich and clarify the evidence from quantitative measures. This knowledge could be used in the future to develop intervention strategies and lifestyle advice tailored to the individual needs of people receiving statin therapy.

419

420

421

422

423

424

425

426

427

428

429

430

431

432

433

434

435

436

Another potential cofounder is that the SAMS group was older and presented greater markers of adiposity, which could have influenced some of the results. While the sample studied in this report is typical of the patients' population at our lipid clinic, and thus includes a variety of statins and doses, we cannot exclude differential impacts of these varying formulations on our measures. Also, although all patients were sedentary and were instructed not to change their physical activity habits during the protocol, this was not objectively monitored, which may be a source of intra- and inter-patient variability. In addition, the relatively small number of participants, particularly in the control and No SAMS groups, and especially in the SAMS-CI sub-analysis, limits our statistical power and could have masked the significance of some of the results. The small number of participants also did not allow for rigorous analyses by sex (although in the SAMS group, baseline analyses did not indicate sex differences in response to drug withdrawal; data not shown). Furthermore, all participants were Caucasian. While we also limited the recruitment to patients between 30 and 60 yrs., primarily to avoid confounding effects of conditions such as sarcopenia on muscle performance measures, this reduces the generalizability of our findings. Our protocol is limited to a short follow-up of two months with two visits (pre- and post-drug withdrawal). A longer follow-up could have led to different conclusions. Finally, our protocol does not allow us to explore or discuss the mechanisms of "true" SAMS.

5. Conclusions

437

438

439

440

441

442

443

444

445

446

447

448

449

450

451

452

453

454

455

456

Whether or not our study population suffered from "true" SAMS or nocebo effects, our data indicate that participants who self-reported SAMS had improved physical function concurrent with decreased subjective symptom intensity following drug withdrawal. Although the negative impacts of statins on muscle function appear small, these could nonetheless have real and substantive effects in certain patients or patient populations. For example, in patients who have experienced sarcopenia or dynapenia, such as the frail elderly or others suffering from various muscle diseases, an additional loss of even a small portion of their functional capacity could contribute to important loss of independence and health-related quality of life (HRQoL). Given the relative ease with which handgrip strength can be measured, the present data certainly warrant future studies on its potential clinical value in assessing functional changes with statin use in these populations. Clearly, the present results need to be validated or recreated in other studies. More prospective data are needed, perhaps in the context of a randomized double-blinded study. Furthermore, they need to be expanded to other statin populations, for example older patients or those in secondary prevention. It also remains of great interest to further efforts to better identify "true" SAMS sufferers and to assess whether functional impacts are greater in this group. Finally, while we focus in this report on objective measures of muscle functions, other impacts of self-reported SAMS such as those on HRQoL need further study.

Acknowledgements

DRJ, JF and JB designed the study. NL provided clinical coordination, SSD, KG and CH participated in data collection, CH managed data validation and entry, PP, CH and DRJ performed statistical analyses. All participated in data interpretation. PP, under the direction of DRJ and PM, wrote the manuscript. All authors critically reviewed and accepted the final version of the article. The authors are grateful to patients for their participation.

References

- 465 1. Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, et al.
- 466 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA
- 467 Guideline on the Management of Blood Cholesterol: A Report of the American College of
- 468 Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
- 469 Circulation. 2019;139(25):e1082-e143.
- Blaha MJ, Martin SS. How do statins work?: changing paradigms with implications
- 471 for statin allocation. J Am Coll Cardiol. 2013;62(25):2392-4.
- 472 3. Boulanger-Piette A, Bergeron J, Desgreniers J, Côté-Levesque M, Brassard D,
- Joanisse DR, et al. [Statin intolerance and associated muscular dysfunctions]. Med Sci
- 474 (Paris). 2015;31(12):1109-14.
- 475 4. Thompson PD, Panza G, Zaleski A, Taylor B. Statin-Associated Side Effects. J Am
- 476 Coll Cardiol. 2016;67(20):2395-410.
- 477 5. Bruckert E, Hayem G, Dejager S, Yau C, Begaud B. Mild to moderate muscular
- 478 symptoms with high-dosage statin therapy in hyperlipidemic patients--the PRIMO study.
- 479 Cardiovasc Drugs Ther. 2005;19(6):403-14.
- 480 6. Selva-O'Callaghan A, Alvarado-Cardenas M, Pinal-Fernandez I, Trallero-Araguas
- E, Milisenda JC, Martinez MA, et al. Statin-induced myalgia and myositis: an update on
- pathogenesis and clinical recommendations. Expert Rev Clin Immunol. 2018;14(3):215-
- 483 24.
- 484 7. Stroes ES, Thompson PD, Corsini A, Vladutiu GD, Raal FJ, Ray KK, et al. Statin-
- associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society

- 486 Consensus Panel Statement on Assessment, Aetiology and Management. Eur Heart J.
- 487 2015;36(17):1012-22.
- 8. Bouitbir J, Sanvee GM, Panajatovic MV, Singh F, Krahenbuhl S. Mechanisms of
- statin-associated skeletal muscle-associated symptoms. Pharmacol Res. 2020;154:104201.
- 490 9. Taylor BA, Thompson PD. Statin-Associated Muscle Disease: Advances in
- 491 Diagnosis and Management. Neurotherapeutics. 2018;15(4):1006-17.
- 492 10. Turner RM, Pirmohamed M. Statin-Related Myotoxicity: A Comprehensive
- 493 Review of Pharmacokinetic, Pharmacogenomic and Muscle Components. J Clin Med.
- 494 2019;9(1).
- Hauser W, Hansen E, Enck P. Nocebo phenomena in medicine: their relevance in
- everyday clinical practice. Dtsch Arztebl Int. 2012;109(26):459-65.
- 497 12. Blacher J, Bruckert E, Farnier M, Ferrieres J, Henry P, Krempf M, et al. [Myalgia
- and statins: Separating the true from the false]. Presse Med. 2019;48(10):1059-64.
- 499 13. Pedro-Botet J, Climent E, Benaiges D. Muscle and statins from toxicity to the
- nocebo effect. Expert Opinion on Drug Safety. 2019;18(7):573-9.
- 501 14. Robinson JG. New insights into managing symptoms during statin therapy.
- Progress in Cardiovascular Diseases. 2019;62(5):390-4.
- 503 15. Alonso R, Cuevas A, Cafferata A. Diagnosis and Management of Statin
- Intolerance. J Atheroscler Thromb. 2019;26(3):207-15.
- 505 16. Rosenson RS, Miller K, Bayliss M, Sanchez RJ, Baccara-Dinet MT, Chibedi-De-
- Roche D, et al. The Statin-Associated Muscle Symptom Clinical Index (SAMS-CI):
- 507 Revision for Clinical Use, Content Validation, and Inter-rater Reliability. Cardiovasc
- 508 Drugs Ther. 2017;31(2):179-86.

- 509 17. Berent T, Berent R, Steiner S, Sinzinger H. Statin-induced muscular side effects at
- rest and exercise An anatomical mapping. Atheroscler Suppl. 2019;40:73-8.
- 511 18. Ashfield TA, Syddall HE, Martin HJ, Dennison EM, Cooper C, Aihie Sayer A. Grip
- 512 strength and cardiovascular drug use in older people: findings from the Hertfordshire
- 513 Cohort Study. Age Ageing. 2010;39(2):185-91.
- 514 19. Krishnan GM, Thompson PD. The effects of statins on skeletal muscle strength and
- exercise performance. Curr Opin Lipidol. 2010;21(4):324-8.
- 516 20. Morville T, Dohlmann TL, Kuhlman AB, Sahl RE, Kriegbaum M, Larsen S, et al.
- 517 Aerobic Exercise Performance and Muscle Strength in Statin Users-The LIFESTAT Study.
- 518 Med Sci Sports Exerc. 2019;51(7):1429-37.
- Noyes AM, Thompson PD. The effects of statins on exercise and physical activity.
- 520 Journal of Clinical Lipidology. 2017;11(5):1134-44.
- 521 22. Parker BA, Capizzi JA, Grimaldi AS, Clarkson PM, Cole SM, Keadle J, et al. Effect
- of statins on skeletal muscle function. Circulation. 2013;127(1):96-103.
- 523 23. Williams PT, Thompson PD. Effects of Statin Therapy on Exercise Levels in
- Participants in the National Runners' and Walkers' Health Study. Mayo Clin Proc.
- 525 2015;90(10):1338-47.
- 526 24. Kawai H, Ihara K, Kera T, Hirano H, Fujiwara Y, Tanaka M, et al. Association
- 527 between statin use and physical function among community-dwelling older Japanese
- 528 adults. Geriatr Gerontol Int. 2018;18(4):623-30.
- 529 25. Mallinson JE, Marimuthu K, Murton A, Selby A, Smith K, Constantin-Teodosiu D,
- et al. Statin myalgia is not associated with reduced muscle strength, mass or protein
- turnover in older male volunteers, but is allied with a slowing of time to peak power output,

- insulin resistance and differential muscle mRNA expression. J Physiol. 2015;593(5):1239-
- 533 57.
- Panza GA, Taylor BA, Dada MR, Thompson PD. Changes in muscle strength in
- 535 individuals with statin-induced myopathy: A summary of 3 investigations. J Clin Lipidol.
- 536 2015;9(3):351-6.
- 537 27. Phillips PS, Haas RH, Bannykh S, Hathaway S, Gray NL, Kimura BJ, et al. Statin-
- Associated Myopathy with Normal Creatine Kinase Levels. Annals of Internal Medicine.
- 539 2002;137(7):581–5.
- 540 28. Feiring DC, Ellenbecker TS, Derscheid GL. Test-Retest Reliability of the Biodex
- 541 Isokinetic Dynamometer. Journal of Orthopaedic & Sports Physical Therapy.
- 542 1990;11(7):298-300.
- 543 29. Mathiowetz V, Weber K, Volland G, Kashman N. Reliability and validity of grip
- and pinch strength evaluations. The Journal of Hand Surgery. 1984;9(2):222-6.
- 545 30. Add-Ins J. Full Factorial Repeated Measures ANOVA Add-In 2014 [Available
- 546 from: https://community.jmp.com/t5/JMP-Add-Ins/Full-Factorial-Repeated-Measures-
- 547 ANOVA-Add-In/ta-p/23904?trMode=source.
- 548 31. Li RC, Wu Y, Maffulli N, Chan KM, Chan JL. Eccentric and concentric isokinetic
- knee flexion and extension: a reliability study using the Cybex 6000 dynamometer. Br J
- 550 Sports Med. 1996;30(2):156-60.
- 551 32. Howard JP, Wood FA, Finegold JA, Nowbar AN, Thompson DM, Arnold AD, et
- al. Side Effect Patterns in a Crossover Trial of Statin, Placebo, and No Treatment. J Am
- 553 Coll Cardiol. 2021;78(12):1210-22.

554 33. Cruz AC, Pedreira M. Patient-and Family-Centered Care and Patient Safety:

reflections upon emerging proximity. Rev Bras Enferm. 2020;73(6):e20190672.

555

556

Supporting information

The study was supported by the Canadian Institutes of Health Research (CIHR grant MOP 114917 to DRJ, JB, and JF [https://cihr-irsc.gc.ca]). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The authors have declared that no competing interests exist.

List supporting information captions

S1 Table. Pre- and post-statin withdrawal plasma variables

SAMS: statin-associated muscle symptoms; FFA: free fatty acids; FBGL: fasting blood glucose level; INS: insulin; TSH: thyroid-stimulating hormone; PTH: parathormone; eGFR: estimated glomerular filtration rate; CRP: C-reactive protein; RF: rheumatoid factor; Cr: creatinine; UR: urea; PA: pyruvic acid; LAC: lactic acid; LDH: lactate dehydrogenase; ALKP: alkaline phosphatase; Ca: calcium; Na: sodium; K: potassium; Mg: magnesium; NH4: ammonia; P: phosphorus; Cl: chloride; Data are expressed as mean ± SD; Post value with * is statistically different from the pre value with p≤0.01; Post value with † is statistically different from the pre value with p<0.05.

S2 Table. Clinical profile of statin users

SAMS: statin-associated muscle symptoms; * Framingham Score: values are means ± SD and ANOVA p=0.06.




Figure 1




Figure 2




Figure 3




Figure 4